Evotec SE American Depositary Shares Earnings Recaps
Q3 2025
Nov 6, 2025
Evotec SE reported a 7% year-on-year decline in revenues for the first nine months of 2025, driven by challenges in the drug discovery market, although its Biologics segment demonstrated strong growth.
Key takeaways
- Group revenues were EUR 535.1 million, with a 12% decline in D&PD (Drug Discovery and Development) business, offset by 11% growth in Just-Evotec Biologics.
- A transformative deal with Sandoz, worth over $650 million, underscores the potential of Evotec’s biologics division.
- Cost-saving measures are expected to exceed EUR 110 million through 2025, aimed at enhancing operational efficiency amid market challenges.
- Positive trends in customer proposals and improved change order performance signal stabilization in the D&PD segment.
- Anticipation of up to four molecules entering Phase II clinical studies in 2026 highlights a strong pipeline and potential for future milestone payments.
Q2 2025
Aug 13, 2025
Evotec SE reported a 5% decline in first-half 2025 revenues to EUR 371 million, reflecting challenges in the Discovery & Preclinical Development segment, while Just - Evotec Biologics continued to thrive with 16% revenue growth.
Key takeaways
- Discovery & Preclinical Development revenues fell by 11%, impacted by temporary changes in the BMS collaboration and a soft drug discovery market.
- Just - Evotec Biologics outperformed expectations, demonstrating strong demand and achieving 16% year-over-year revenue growth.
- A planned sale of the Toulouse site to Sandoz aligns with Evotec's strategy to enhance its capabilities in biologics manufacturing with a scalable, asset-light model.
- A strategic reorganization is underway to simplify the business structure and enhance operational accountability.
- Market conditions remain challenging, particularly for early-stage biotech funding, but signs of recovery are emerging.